Financial Performance - Corbus Pharmaceuticals reported a net loss of approximately $13.8 million, or $1.15 per diluted share, for Q3 2024, compared to a net loss of approximately $10.1 million, or $2.27 per diluted share for the same period in 2023[9]. - The total operating loss for Q3 2024 was approximately $15.5 million, compared to $9.5 million in the same period in 2023[10]. - The total stockholders' equity increased to $150.5 million as of September 30, 2024, compared to a deficit of $6.9 million at the end of 2023[20]. Operating Expenses - Operating expenses increased by $6.0 million to approximately $15.5 million for Q3 2024, primarily due to a $3.2 million increase in CRB-701 clinical trial costs and higher compensation costs of $1.6 million[10]. Clinical Trials and Data - The company completed enrollment of the dose escalation part of the Phase 1 clinical trial of CRB-701, with first data expected in Q1 2025, showing a 44% overall response rate (ORR) in metastatic urothelial cancer and 43% in cervical cancer at doses ≥ 1.2 mg/Kg[4]. - CRB-913 pre-clinical data presented at Obesity Week 2024 indicated a dose-response achieving up to 38% weight loss in diet-induced obesity mice, with levels in the brain being 15-fold lower than monlunabant[6]. - The company presented promising efficacy and safety data for CRB-701 at ASCO 2024, indicating the drug is clinically active with a differentiated safety profile[2]. - CRB-601, a monoclonal antibody, is expected to dose the first patient in Q4 2024 for the treatment of advanced solid tumors[8]. Cash and Funding - As of September 30, 2024, the company had $159.4 million in cash, cash equivalents, and investments, expected to fund operations through Q3 2027[11]. - The company raised $35.6 million in net proceeds during Q3 2024 through its ATM program by issuing 663,730 shares[11].

Core Viewpoint - Corbus Pharmaceuticals Holdings, Inc. will participate in the Guggenheim Securities Healthcare Innovation Conference, highlighting its commitment to innovative treatments in oncology and obesity [1][2]. Company Overview - Corbus Pharmaceuticals is focused on oncology and obesity, with a diversified portfolio aimed at addressing serious illnesses through innovative scientific approaches [2]. - The company's pipeline includes: - CRB-701: A next-generation antibody drug conjugate targeting Nectin-4 on cancer cells [2]. - CRB-601: An anti-integrin monoclonal antibody that blocks TGFβ activation on cancer cells [2]. - CRB-913: A peripherally restricted CB1 receptor inverse agonist for obesity treatment [2]. - Corbus is headquartered in Norwood, Massachusetts [2]. Event Details - The Guggenheim Securities Healthcare Innovation Conference will take place from November 11-13, 2024, with a specific fireside chat and one-on-one investor meetings scheduled for November 12, 2024, at 10:00 a.m. ET [1][2].

Corbus Pharmaceuticals (CRBP) closed the last trading session at $59.70, gaining 2.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $85.86 indicates a 43.8% upside potential. The average comprises seven short-term price targets ranging from a low of $76 to a high of $105, with a standard deviation of $9.30. While the lowest estimate indicates an increase of 27.3% from the current ...

NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), today announced the appointment of Winston Kung to its Board of Directors. The appointment was effective as of August 16, 2024. Mr. Kung will also chair the Audit Committee. "With this track record of success in both the pharma industry and on Wall Street, Winston has earned a welldeserved reputation for his leadership and financial acumen," said Alan F. Holmer, Chairman of the ...

Corbus Pharmaceuticals (CRBP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system ...

Corbus Pharmaceuticals (CRBP) closed the last trading session at $53.60, gaining 0.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $82.67 indicates a 54.2% upside potential. The average comprises six short-term price targets ranging from a low of $76 to a high of $88, with a standard deviation of $4.27. While the lowest estimate indicates an increase of 41.8% from the current pr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ to_________. Commission File Number: 001-37348 Corbus Pharmaceuticals Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4348039 (Sta ...

Exhibit 99.1 Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update • Clinical update presented at ASCO 2024 for CRB-701 showed continued differentiated safety and encouraging efficacy in patients with metastatic urothelial cancer or cervical cancer • CRB-701 Phase 1 dose escalation underway in USA and Europe for patients with metastatic urothelial cancer and other nectin-4 enriched tumors and is on schedule for completion in Q4 2024 • Cash runway extended throu ...

Clinical update presented at ASCO 2024 for CRB-701 showed continued differentiated safety and encouraging efficacy in patients with metastatic urothelial cancer or cervical cancer CRB-701 Phase 1 dose escalation underway in USA and Europe for patients with metastatic urothelial cancer and other nectin-4 enriched tumors and is on schedule for completion in Q4 2024 Cash runway extended through Q3 2027 with $147 million of cash & investments at June 30, 2024 NORWOOD, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Co ...

BTIG Virtual Biotechnology Conference Date: August 13-14, 2024 Format: Invitation only, one on one and small group investor meetings Note: Investors interested in attending and meeting with management should contact their Wedbush representatives. Forward-Looking Statements NORWOOD, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in two invest ...